EUCTR2008-002317-40-DE进行中（未招募）不适用
A phase IIa, multi-center, randomized, double-blind, vehicle-controlled study to determine antipsoriatic efficacy and safety of topical CEP-701 (lestaurtinib) cream formulations in patients with psoriasis vulgaris - POC Psoriasis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •All of the following criteria have to be met for inclusion of a patient in the study:
- •male patients aged 18 years or older;
- •patients with psoriasis vulgaris in a chronic stable phase and at least one plaque with a treatment area of approximately 25 - 50 cm2 and mild to moderate severity;
- •the physical examination must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study;
- •sexually active males should use condom with intravaginal spermicide; male patients have to use contraception for a minimum of two days after last treatment (over 5 elimination half lives of CEP-701 which is 7 hours). The female partners of childbearing potential should either be surgically sterile (hysterectomy or tubal ligation), or should use a highly effective medically accepted contraceptive regimen: systemic contraceptive (oral, implant, injection), diaphragm or cervical cap with intravaginal spermicide, intrauterine device (IUD), or condom with intravaginal spermicide;
- •written informed consent obtained.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients are to be excluded from the study when one or more of the following conditions are met:
- •patients who require systemically acting medications for the treatment of psoriasis, which might counter or influence the study objectives, e.g. corticosteroids, cytostatics;
- •local treatment with antipsoriatics (except for salicylic acid in vaseline) in the 4 weeks preceding and during the study (corticosteroids 8 weeks) on the plaques to be treated;
- •systemic treatment with antipsoriatics in the three months preceding and during the study;
- •treatment with systemic or locally acting medications which might counter or influence the study aim (e.g. glucocorticosteroids, MAO inhibitors, anti-epileptic drugs, anti-psychotic drugs) or medications which are known to provoke or aggravate psoriasis, e.g. ß-blocker, antimalarial and lithium drugs within two weeks before the beginning of the study and during the study;
- •known allergic reactions to the active ingredients or other components of the study preparations, occlusive dressing, or test chambers;
- •evidence of drug abuse;
- •UV-therapy within four weeks before beginning and during the study and extensive natural UV-exposure;
- •symptoms of a clinically significant illness that may influence the outcome of the study in the four weeks before and during the study;
- •treatment with an investigational product/device in another clinical trial in the four weeks preceding and during the study;
- •in the opinion of the investigator or physician performing the initial examination the patient should not participate in the study, e.g. due to probable noncompliance or inability to understand the study and give adequately informed consent;
- •patient is institutionalized because of legal or regulatory order.
研究者
相似试验
进行中（未招募）
不适用
A phase IIa, multi-center, randomized, double-blind study to evaluate the anti-mycotic and anti-inflammatory efficacy of topical combinational product LAS 41003 versus corresponding mono-substances in patients with candida infections in intertriginous areas at the trunk - Candida intertriginosaEUCTR2009-016627-56-DEAlmirall Hermal GmbH
进行中（未招募）
不适用
A Phase IIa, multi-centre, randomised, double-blind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of a new regimen and new formulation of MCI-186 in subjects with acute ischemic strokeAcute ischemic strokeEUCTR2008-003397-17-NLMitsubishi Tanabe Pharma Corporation
进行中（未招募）
不适用
A Phase IIa, multi-centre, randomised, double-blind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of a new regimen and new formulation of MCI-186 in subjects with acute ischemic strokeAcute ischemic strokeMedDRA version: 9.1Level: LLTClassification code 10055221Term: Ischemic strokeEUCTR2008-003397-17-GBMitsubishi Tanabe Pharma Corporation36
已完成
2 期
A Phase IIa, multi-centre, randomised, double-blind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of a new regimen and new formulation of MCI-186 in subjects with acute ischemic strokeAcute Ischemic Stroke (AIS) - stroke10011954NL-OMON35656Mitsubishi Pharma Corporation12
进行中（未招募）
不适用
A Phase IIa, multi-centre, randomised, double-blind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of a new regimen and new formulation of MCI-186 in subjects with acute ischemic strokeEUCTR2008-003397-17-FIMitsubishi Tanabe Pharma Corporation36